Antepartum Fetal Surveillance
Customize your policy alerts
Sign up for Aetna Policy 0088 alerts
Get alerted when Policy 0088 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity and coverage for antepartum fetal surveillance tests (NST, CST, BPP, modified BPP, umbilical artery and middle cerebral artery Doppler, and measurement of sFlt-1/PlGF ratio) for pregnant women with specified risk factors and clinical scenarios, per ACOG guidance. Applies to in-office and in-hospital testing reviewed by Aetna.
No material clinical or coverage changes in this revision.
Coverage Criteria for Antepartum Fetal Surveillance
inv-01: Antepartum fetal surveillance — timing and indications
Covered when ALL of the following are met
Examples of high-risk conditions include bleeding, chronic or pregnancy-induced hypertension, collagen vascular disease (including antiphospholipid syndrome), fetal growth restriction, gestational diabetes, impaired renal function, maternal heart disease (NYHA Class III or IV), oligohydramnios, significant isoimmunization, steroid-dependent or poorly controlled asthma.
inv-02: Repeat testing
Covered when ANY of the following persistence conditions apply
inv-03: CST or full BPP after abnormal NST
Covered when the following sequenced testing applies
inv-04: Doppler velocimetry indications (umbilical artery and MCA)
Covered when ALL of the following are met
Decisions about timing of delivery should integrate Doppler results with other fetal well-being tests and maternal status.
inv-05: Preeclampsia biomarker testing
Covered when ALL of the following are met
Test should be used in conjunction with other clinical assessments to aid risk assessment for progression to preeclampsia with severe features.
inv-06: Clinical evidence and implied coverage stance
Summary of clinical utility and evidence-based guidance from the document:
Document BPP components and resulting score when performed.
Doppler of vessels other than umbilical artery and MCA is considered investigational for routine surveillance.
inv-07: Use of umbilical artery Doppler
Covered/appropriate when used in the evaluation of suspected intrauterine growth restriction (IUGR) or other high-risk fetal conditions and integrated with other fetal testing:
Not recommended as routine screening in low-risk pregnancies; evidence shows Doppler reduces interventions and may improve outcomes in IUGR.
inv-08: Use of MCA PSV
Appropriate for assessment of fetal anemia in red-cell alloimmunization:
High sensitivity (reported ~93%) supports clinical applicability to reduce cordocentesis.
inv-09: Third-trimester UAD in late SGA
Useful as part of multi-test assessment in suspected late SGA (>=32 weeks):
Predictive accuracy highest for perinatal mortality (AUC reported ~0.90); limited utility as a standalone test.
inv-10: Doppler in multiple gestations, TTTS, and TAPS
Doppler incorporated into surveillance for monochorionic twin complications per specialty guidance:
Refer patients meeting criteria for fetal intervention (eg, laser) to a specialized fetal intervention center.
inv-11: Evidence-supported clinical indications
Clinical scenarios and evidence where sFlt-1/PlGF measurement has demonstrated utility:
Utility diminishes after 35 weeks; use with clinical assessment.
Investigators suggested consideration of implementation in this population.
Prospective validation and standardized cut‑offs needed.
inv-12: Evidence and guideline references
Clinical evidence and guideline context informing surveillance choices
See references list for specific guideline citations.
The policy lists specific tests and procedures considered experimental, investigational, or unproven because effectiveness has not been established. Examples include remote non‑stress testing (home, tele‑monitored, or virtual NST), Doppler studies of the ductus venosus and vessels other than the middle cerebral artery or umbilical artery for fetal growth surveillance, measurement of serum YKL‑40 for evaluation of pre‑eclampsia or SGA, and ophthalmic artery Doppler for prediction of pre‑eclampsia. The policy also identifies certain CPT codes (e.g., 83520, 93886, 93888) associated with these investigational indications and notes they are not covered for those purposes.
The document indicates that routine uterine artery Doppler screening is not recommended. Systematic reviews and guideline assessments have concluded there is insufficient evidence to support routine uterine artery Doppler as a screening test in average‑risk or unselected populations, and standards for technique, timing, and abnormality thresholds are inconsistent across studies.
Evidence from randomized trials and systematic reviews does not support use of routine Doppler ultrasonography (uterine, umbilical, or fetal) as a population‑level screening test in low‑risk obstetric patients. Cochrane and other reviews found no clear benefit on primary outcomes (perinatal death or neonatal morbidity) when Doppler was applied routinely in unselected pregnancies; guideline statements similarly recommend Doppler primarily for evaluation when clinical concern for IUGR or other high‑risk conditions exists rather than for routine screening.
Ophthalmic artery Doppler findings reported in cohorts showed predictive performance similar to uterine artery indices in some studies (for example, PMDV AUC ≈0.73), but the authors cautioned that these studies enrolled women with pre‑eclampsia risk factors and therefore results may not be generalizable to routine screening of all pregnant women. External validation in broader populations was recommended.
The policy notes that no single biomarker had sufficient test performance for routine clinical use alone. Combined prediction models (for example, sFlt‑1/PlGF with clinical factors or other biochemical markers) showed improved detection rates in some studies, but these combined models lack extensive external validation and require further evaluation before routine implementation.
The excerpt provided does not include explicit lists of exclusions by benefit plan; it summarizes investigational tests and clinical guidance but does not define plan‑specific exclusionary language in the text shown.
This Clinical Policy Bulletin provides a general, partial description of plan or program benefits and does not constitute a contract. Providers should consult specific plan documents and contracts for definitive coverage determinations and are responsible for treatment decisions; Aetna does not guarantee coverage or outcomes based on this bulletin alone.
Antepartum fetal surveillance modalities (NST, CST, BPP, modified BPP, umbilical artery Doppler) performed for indications not listed as medically necessary in the policy are considered experimental, investigational, or unproven. Billing for these tests when ordered for non‑listed indications may be subject to denial.
Routine fetal Doppler and uterine artery Doppler performed in low‑risk or unselected populations have not demonstrated benefit for mother or baby in randomized trials and systematic reviews. Therefore, routine Doppler screening in low‑risk populations is not supported and surveillance should be targeted to pregnancies with clinical risk factors or suspicion of fetal compromise.
The policy emphasizes that use of Doppler studies as routine screening in unselected pregnancies is not supported by evidence. Doppler velocimetry (particularly umbilical artery Doppler) is most appropriate when there is clinical suspicion of IUGR or other high‑risk fetal conditions and should be interpreted alongside other fetal assessments.
Although combined screening approaches (e.g., sFlt‑1/PlGF with PAPP‑A, BMI, or other markers) showed promising detection rates in some studies, the policy states that further studies are needed to evaluate combined tests in low‑risk populations and to address variability due to small sample sizes and heterogeneous pathophysiology.
Within the provided text there are no explicit statements
Coding and Clinical Measurements
| 59020 | Fetal contraction stress test. |
| 59025 | Fetal non-stress test. |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, after first trimester (> or = 14 weeks 0 days), transabdominal approach; single or first gestation. |
| 76810 | Each additional gestation (List separately in addition to code for primary procedure). |
| 76818 | Fetal biophysical profile; with non-stress testing. |
| 76819 | Fetal biophysical profile; without non-stress testing. |
| 76820 | Doppler velocimetry, fetal; umbilical artery. |
| 76821 | Doppler velocimetry, fetal; middle cerebral artery. |
| 0482U | Obstetrics (preeclampsia), biochemical assay of soluble fmslike tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF), serum, ratio reported for sFlt1/PlGF, with risk of progression for preeclampsia with severe features within 2 weeks. |
| 0524U | Obstetrics (preeclampsia), sFlt-1/PlGF ratio, immunoassay, utilizing serum or plasma, reported as a value. |
| 83520 | Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified [not covered for serum YKL-40]. |
| 93886 | Transcranial Doppler study of the intracranial arteries; complete study [not covered for prediction of pre-eclampsia]. |
| 93888 | Transcranial Doppler study of the intracranial arteries; limited study [not covered for prediction of pre-eclampsia]. |
| D68.61 | Antiphospholipid syndrome. |
| E10.10 - E10.A2 | Type 1 diabetes mellitus. |
| E11.00 - E11.9 | Type II diabetes mellitus. |
| I50.1 - I51.9 | Heart failure. |
| J45.20 - J45.998 | Asthma [steroid dependent or poorly controlled]. |
| FDA May 2023 | Regulatory approval noted for sFlt-1:PlGF test in hospitalized singleton patients with hypertensive disorders |
| No codes listed |
Provider Actions, Prior Authorization, and Documentation
Prior authorization — covered CPT/HCPCS codes require criteria to be met
CPT/HCPCS codes for antepartum fetal surveillance (e.g., 59020, 59025, 76805, 76810, 76818, 76819, 76820, 76821, 0482U, 0524U) are listed in the policy as covered when the policy's selection criteria are met; ensure the clinical indications and gestational-age thresholds in the policy are documented when billing these codes and follow any payer prior-authorization rules that apply.
Prior authorization may be required for remote monitoring
Remote/home non‑stress testing and telemonitoring are described as emerging and feasible alternatives with evidence of non‑inferiority in selected high‑risk pregnancies; confirm plan requirements and prior‑authorization rules for home fetal monitoring devices and telemonitoring programs before ordering or billing.
- Studies cited show feasibility and non‑inferiority (e.g., INVU study: >90% acceptable NSTs remotely).
- Policy explicitly advises to confirm payer policy for prior authorization for home fetal monitoring and telemonitoring.
Prior authorization expectation for Doppler in suspected IUGR
Umbilical artery Doppler velocimetry is supported when intrauterine growth restriction (IUGR) is suspected or diagnosed and should be interpreted with other fetal assessments; routine Doppler screening in low‑risk pregnancies is not supported by evidence.
- Use Doppler to inform timing of delivery in suspected IUGR and integrate results with NST, BPP, amniotic fluid assessment, and maternal status.
- Policy notes Doppler reduces some interventions in IUGR but is not recommended as routine screening in low‑risk populations.
No specific prior authorization stated in background text
The background and policy text do not specify any standalone prior‑authorization requirements for the described antepartum fetal surveillance tests in this segment; practitioners should still verify plan‑specific preauthorization rules separately.
- Background sections summarize clinical evidence but do not list explicit prior‑authorization procedures or rules.
- Policy history and administrative notes further indicate plan provisions govern coverage determinations.
Prior authorization / regulatory context for sFlt‑1/PlGF assays
The document references FDA approval (May 2023) of the sFlt‑1/PlGF test for hospitalized singleton patients with hypertensive disorders and recommends using the test with other clinical assessments; it does not define payer prior‑authorization procedures for this assay.
- FDA approval noted May 2023 for sFlt‑1:PlGF in hospitalized singleton pregnancies with hypertensive disorders.
- Policy advises the test should be used in conjunction with other laboratory tests and clinical assessments.
No explicit prior authorization requirements for antepartum surveillance in this excerpt
This excerpt does not list specific prior‑authorization requirements for routine antepartum fetal surveillance services (NST, CST, BPP, modified BPP, Doppler); providers should follow plan rules and document clinical indications per the policy when requesting coverage.
- Policy outlines medical‑necessity criteria but the excerpt contains no explicit preauthorization triggers.
- Providers remain responsible for verifying plan‑specific authorization requirements.
Prior authorization not specified in policy history section
Policy history and review dates are provided, but this section does not list procedure codes requiring prior authorization; confirm authorization requirements with the payer for the specific patient and service.
- Last review date and effective/next review dates are shown; policy content does not substitute for plan authorization rules.
- Clinical Policy Bulletins are descriptive and not a guarantee of coverage.
Order CST or full BPP after abnormal NST as indicated
Following an abnormal NST or modified BPP, a contraction stress test (CST) or a full biophysical profile (BPP) is considered medically necessary; subsequent management should be based on CST/BPP results, gestational age, oligohydramnios severity, and maternal condition.
- Policy statement: 'A CST or full BPP is considered medically necessary following an abnormal NST or modified BPP.'
- Management decisions should incorporate CST/BPP findings and clinical context.
CST is uncommon — consider NST/BPP first
The CST is described as rarely used in current clinical practice; consider less invasive options (NST, BPP) before performing a CST when clinically appropriate.
- CST overview: test lasts until 3 moderate contractions in 10 minutes; often not used clinically.
- Policy emphasizes CST's uncommon role and suggests alternatives be considered first.
Use UAD as part of a sequential, multi‑test approach in late SGA
For suspected late small‑for‑gestational‑age (SGA) fetuses (≥32 weeks), uterine artery Doppler (UAD) or other third‑trimester UAD assessments should be used as part of a multi‑test strategy rather than relied on as a standalone test to guide management.
- Policy notes limited predictive ability of UAD as a stand‑alone test and recommends combining Doppler with other fetal assessments.
- Third‑trimester abnormal UAD is moderately useful for predicting perinatal death in late SGA but should inform, not dictate, decisions.
No mandated testing order or step therapy sequencing specified
The policy does not mandate a specific testing sequence or step‑therapy algorithm beyond the recommended pathway after abnormal NST; studies evaluating combinations of markers and Doppler are summarized but no required stepwise ordering is specified.
- Document summarizes combination models and detection rates but explicitly states no mandated testing order is described.
- Providers should apply clinical judgment and follow policy criteria when selecting tests.
Document clinical indications, risk factors, and gestational age for testing
Document clinical indications and gestational age when ordering antepartum fetal surveillance tests; if repeat testing is performed, document persistence of the condition or acute changes (e.g., decreased fetal movement) that justify repeat testing.
- Policy requires tests be ordered for specified maternal, pregnancy‑related, or fetal risk factors and notes gestational‑age thresholds for initiation (e.g., 32–34 weeks or 26 weeks for high‑risk conditions).
- Repeat testing is medically necessary if the provoking condition persists or with clinical deterioration.
Document BPP components and scores
When performing a Biophysical Profile (BPP) or modified BPP, document each component and the resulting score; for modified BPP, document NST findings and the amniotic fluid assessment used.
- BPP components to document: amniotic fluid index, fetal breathing, fetal movement, fetal tone, and NST, with score 0–10.
- Modified BPP: document NST findings and amniotic fluid index.
Document integration of Doppler results with other assessments to support management
When umbilical artery Doppler is used for surveillance of suspected IUGR, document how Doppler results were integrated with other fetal assessments (amniotic fluid, NST, CST, BPP) and maternal status to support timing‑of‑delivery decisions.
- ACOG guidance cited: decisions regarding timing of delivery should combine Doppler findings with other tests of fetal well‑being and maternal monitoring.
- Policy emphasizes interpreting Doppler in the broader clinical context rather than as a standalone determinant.
Document exact Doppler/biomarker parameters and cutoffs used
Studies report specific measured Doppler and biomarker parameters and cutoffs (for example, ophthalmic artery PMDV >22.11 cm/s); document the exact parameter measured, gestational age, and any combined model components used when reporting these results.
- Example cutoff: ophthalmic artery PMDV >22.11 cm/s associated with PE prediction (sensitivity 70%, specificity 75%).
- Policy notes that combined models incorporate clinical variables and biomarkers; document components for clinical interpretation.
Documentation note — sFlt‑1/PlGF approval noted; verify authorization process
The policy notes no explicit documentation or prior‑authorization procedural requirements in these sections but highlights the FDA approval (May 2023) for the sFlt‑1/PlGF assay in hospitalized singleton patients; providers should follow plan rules for authorization and document clinical context when ordering this test.
- FDA approval for sFlt‑1:PlGF in May 2023 is noted; the test should be used with other clinical assessments.
- No procedural prior‑authorization process for the assay is defined in the excerpt—verify with payer.
Use policy glossary terms in clinical documentation
Use the policy's glossary terms (e.g., fetal growth restriction, oligohydramnios, polyhydramnios) in clinical documentation to clearly support the indication for surveillance testing.
- Examples: Fetal growth restriction defined as estimated fetal weight or abdominal circumference <10th percentile; oligohydramnios defined by deepest vertical pocket ≤2 cm or AFI ≤5 cm.
- Using standard terminology from the policy helps substantiate medical necessity.
Denial risk — experimental, investigational, or unproven tests
Tests identified in the policy as experimental, investigational, or unproven (including remote non‑stress testing, Doppler of ductus venosus or vessels other than umbilical/MCA, uterine artery Doppler for routine screening, serum YKL‑40, ophthalmic artery Doppler, and Preeclampsia Screen|T1) may not be established and could trigger coverage denial if billed for the excluded indications.
- Policy lists remote NST (home/tele‑monitored) and several Doppler/biomarker tests as experimental or unproven for the indications noted.
- Billing these procedures for indications not listed as medically necessary risks denial.
Denial risk — routine Doppler in low‑risk populations not supported
Routine use of uterine artery Doppler or routine Doppler screening in low‑risk or unselected populations is not supported by the evidence; ordering such routine Doppler surveillance without clinical indication could risk denial.
- Cochrane review cited: routine fetal and umbilical Doppler in low‑risk populations did not improve primary outcomes and is not supported for routine screening.
- Policy states Doppler is most applicable in already defined high‑risk populations.
Denial risk — order Doppler only with documented clinical indication
The policy emphasizes that umbilical or uterine artery Doppler should not be used as routine screening in low‑risk or unselected pregnancies; order Doppler testing only when clinical suspicion (e.g., suspected IUGR, oligohydramnios, multiple gestation complications) is documented to support coverage.
- ACOG guidance quoted: Doppler not shown to be of value as a screening test in the general obstetric population.
- Policy recommends Doppler primarily when IUGR is suspected and to integrate findings with other assessments.
No explicit coverage/billing rules in background — verify payer requirements
The policy's background sections do not state explicit authorization, coverage, or billing requirements; providers should rely on the documented medical‑necessity criteria in the policy and confirm any payer authorization or billing rules separately.
- Background and evidence summaries are descriptive and do not replace plan authorization rules.
- Confirm coverage and preauthorization processes with the payer before billing.
No explicit preauthorization triggers stated — confirm with payer
The document segment does not state explicit preauthorization triggers; nevertheless, providers remain responsible for verifying plan‑specific prior‑authorization requirements before ordering and billing services.
- Policy describes clinical indications and FDA approval context but does not list automatic preauthorization triggers.
- Verify member's plan provisions for prior authorization.
Background and Evidence Summary
Antepartum fetal surveillance is intended to assess risk of adverse perinatal outcomes related to utero‑placental insufficiency and fetal hypoxia. Common surveillance methods include maternal fetal movement assessment, NST, BPP (five components scored 0–10), modified BPP, and Doppler velocimetry of the umbilical and middle cerebral arteries. Testing is targeted to pregnancies with maternal or pregnancy‑related risk factors (for example, decreased fetal movement, IUGR, oligohydramnios, isoimmunization, multiple gestation with growth discrepancy, hypertensive disorders, or prior fetal demise) and should be timed so that interventions are possible based on gestational age.
inv-21: Evidence point — Routine fetal and uterine artery Doppler in low-risk populations not shown to benefit mother or baby
Summary evidence point
Cochrane reviews and guideline assessments found no improvement in perinatal mortality or neonatal morbidity with routine Doppler in low‑risk groups.
Recommendations and coverage considerations in the policy are informed by major guideline sources including ACOG practice bulletins and committee opinions (for example, guidance on umbilical artery Doppler and management of preeclampsia) and systematic evidence reviews. These guidelines support targeted use of Doppler in suspected IUGR and caution against routine Doppler screening in low‑risk populations.
Clinical evidence summarized in the policy includes randomized trials, cohort studies, and systematic reviews. Cochrane reviews found no benefit from routine fetal/umbilical Doppler screening in unselected populations, while trials in high‑risk pregnancies showed that umbilical artery Doppler can reduce interventions and perinatal death. Evidence for biomarkers such as sFlt‑1/PlGF demonstrates utility for short‑term rule‑out of preeclampsia (for example, ratio ≤38 in PROGNOSIS) and improved predictive accuracy when combined with clinical or ultrasound markers, but broader validation and implementation considerations remain.
Definitions and Test Descriptions
Policy Revision History
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.